Latest News

Thursday, August 16, 2018

Intrathecal Baclofen More Effective Than Oral Medication for Treating Pain in Patients With Poststroke Spasticity

Results from the SISTERS trial (NCT01032239) show that intrathecal administration (ITB Therapy; Medtronic, Dublin, Ireland) of baclofen (Lioresal Intrathecal; Saol Therapeutics, Roswell, GA) is a more…

Read the full story

Wednesday, August 15, 2018

First-in-Class RNAi Treatment for Hereditary Transthyretin-Mediated Amyloidosis

The US Food and Drug Administration (FDA) has approved patisiran (Onpattro; Alnylam Pharmaceuticals, Cambridge, MA) for treatment of polyneuropathy in adults with hereditary transthyretin-mediated amy…

Read the full story

Wednesday, August 15, 2018

Free Online Training for Professionals to Develop Exercise Programs for Those With Parkinson's Disease

An online training program has been launched by the Brain Grant Foundation to help professionals develop safe and effective exercise programming for people living with Parkinson’s disease (PD). …

Read the full story

Monday, August 13, 2018

New Drug Application Accepted for Midazolam Nasal Spray for Treating Patients with Acute Repetitive Seizures

The Food and Drug Administration (FDA) has accepted a new drug application (NDA) filing for midazolam nasal spray (USL261; UCB, Atlanta, GA) for the treatment of persons with epilepsy who experience a…

Read the full story

Thursday, August 09, 2018

SPECIAL REPORT New Guideline for Clinical Management of Persons in Vegetative or Minimally Conscious States

The American Academy of Neurology (AAN), American Congress of Rehabilitation Medicine (ACRM), and the National Institute on Disability, Independent Living, and Rehabilitation Research released a new g…

Read the full story

Wednesday, August 08, 2018

Funding Received for Phase 2 Trial of Xanomeline-Tropsium Chloride

A $42-million financing round has been completed and will be used to finance a phase 2 trial of xanomeline-tropsium chloride (KarXT; Karuna, Boston, MA) for treatment of persons with schizophrenia. …

Read the full story

Tuesday, August 07, 2018

Braintest App Has Equivalent Sensitivity and Specificity as SAGE Test for Mild Cognitive Impairment

There is an app (BrainTest, Columbus, OH) used to detect mild cognitive impairment (MCI). It is a clinically validated, digital version of the paper and pen Self-Administered Gerocognitive Exam (SAGE)…

Read the full story

Saturday, August 04, 2018

Folic Acid During Pregnancy for Women Taking Antiepileptic Drugs May Improve Language Development for Their Children

A study published in Neurology evaluated the relationship between language delays in children born to women taking antiepileptic drugs (AEDs) with and without folic acid supplementation. The study was…

Read the full story

Thursday, August 02, 2018

Heading the Ball in Soccer May Affect Women's and Men's Brains Differently

In a new study from researchers at the Albert Einstein College of Medicine (Radiology. 2018;July 31), imaging findings suggest that heading the ball in soccer may affect women's brains differently…

Read the full story

Wednesday, August 01, 2018

First Patient Enrolled in Phase 3 Study of Athersys’ Stem Cell Treatment for Patients who Experienced Ischemic Stroke

The first patient has been enrolled in a phase 3 study, MASTERS-2 (NCT03545607), which is a pivotal study that has received special protocol assessment, fast-track designation, and regenerative medici…

Read the full story

Tuesday, July 31, 2018

New Drug Application for Cladribine Filed and Accepted

Cladribine (Mavenclad; EMD Serono, Rockland, MA) is an investigational oral therapy for patients with relapsing forms of multiple sclerosis (MS). The drug has proposed dosing of a maximum of 20 days o…

Read the full story

Monday, July 30, 2018

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safely in 5 persons with mild-…

Read the full story

Monday, July 30, 2018

Aggressive Treatment of Hypertension Promotes Healthy Brains and Hearts

Aggressive lowering of systolic blood pressure (BP) reduces the risk of mild cognitive impairment (MCI) and combined MCI and dementia. In the SPRINT trial (NCT01206062), 2 strategies for managing high…

Read the full story

Friday, July 27, 2018

Positive Results in Phase 2 Trial of BAN2401 for Treatment of Persons With Alzheimer’s Disease

Detailed results of a phase 2 study (NCT01767311) of BAN2401 (Eisai, Woodcliff Lake, NJ and Biogen, Cambridge, MA) were presented at the Alzheimer's Association International Conference (AAIC) 201…

Read the full story

Thursday, July 26, 2018

Crenezumab and Gantenerumab In Phase 3 Trials for Treating Persons with Alzheimer’s Disease

Crenezumab and Gantenerumab are 2 monoclonal antibodies directed against amyloid-ß (Aß) soluble and oligomeric forms. Crenezumab more specifically targets oligomers, whereas ganteneru…

Read the full story
Load More